SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology & Drugs -- Ignore unavailable to you. Want to Upgrade?


To: SusieQ1065 who wrote (98)7/3/2002 8:55:55 AM
From: SusieQ1065  Read Replies (2) | Respond to of 232
 
08:49 ET ADRX Andrx cut to Mkt Outperform at Goldman (21.69)
Goldman Sachs downgrades to MKT OUTPERFORM from Trading Buy. While believes ADRX is well positioned for a favorable ruling and launch of several generics in the coming months, believes lack of clarity on the specific timing of these catalysts warrants a Mkt Outperform rating. Estimates unchanged and price target remains $63.